Andy Andrews
- Halozyme (HALO) has signed a global collaboration and license agreement with Incyte (INCY) to potentially use the former’s Enhanze drug delivery technology with the latter’s INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative neoplasms candidate currently
